ClinicalTrials.Veeva

Menu

Digoxin Drug-Drug Interaction With Lurasidone HCl

Sumitomo Pharma logo

Sumitomo Pharma

Status and phase

Completed
Phase 1

Conditions

Schizophrenia

Treatments

Drug: Lurasidone

Study type

Interventional

Funder types

Industry

Identifiers

NCT01082289
D1050279

Details and patient eligibility

About

The objective of this study is to evaluate the pharmacokinetic profile of digoxin when administered alone and when administered with repeated dose of lurasidone 120mg.

Enrollment

24 patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Male and female 18 to 65 years of age
  • BMI >= 19.5 and <= 37 kg/m2
  • No clinically relevant abnormal laboratory values

Exclusion criteria

  • History or presence of renal or hepatic insufficiency
  • Participated in a clinical trial in the past 30 days
  • Use of con meds that prolong the QT/QTc taken within 28 days prior to study drug administration

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems